BAJAJ BROKING

Notification close image
No new Notification messages
card image
Euro Pratik Sales Ltd IPO
Apply for the Euro Pratik Sales Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Biocon Ltd. - History, Overview & Future Outlook

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00
Biocon Ltd. - History, Overview & Future Outlook

Biocon Ltd. is one of India’s top biotech firms. It makes and sells pharmaceutical products, biologics, and enzymes. The company works across the full drug development cycle—from research to final production. Biocon uses fermentation-based processes to keep medicines affordable. Its key drugs include Acarbose, Pioglitazone, Repaglinide, and Rosiglitazone for diabetes.

In its biologics segment, it manufactures Insulin, Erythropoietin (EPO), Filgrastim (G-CSF), Streptokinase, and Monoclonal Antibodies. It also makes cholesterol-lowering statins like Lovastatin and Atorvastatin. Biocon’s enzymes are used in industries like food, brewing, textiles, and paper.

BIOCON LIMITED.

Trade

360.21.95 (0.54 %)

Updated - 16 September 2025
361.95day high
DAY HIGH
358.35day low
DAY LOW
967894
VOLUME (BSE)

About Biocon Ltd.

Details

Information

Founded Year

1978

Industry Type

Biotechnology and Pharmaceuticals

Headquarters

Bengaluru, India

Key People

Dr. Kiran Mazumdar-Shaw (Chairperson), Siddharth Mittal (CEO & MD)

History

Biocon was started in 1978 as a joint venture between Kiran Mazumdar-Shaw and Ireland-based Biocon Biochemicals. It began in a small shed in Bengaluru with just three staff members. Its first exports were papain and isinglass—enzymes used in brewing—sent to the U.S. and Europe.

In 1980, Biocon bought 20 acres of land on Hosur Road for ₹6 lakh and began building what is now its corporate office. This move laid the groundwork for its growth into a global biotech player.

Industry and Sector

Biocon operates in the global biopharmaceutical sector. It focuses on biosimilars, generics, and research services. The company aims to offer affordable healthcare solutions and serves customers in the U.S., Europe, and other markets. In India, it markets treatments for diabetes, cancer, and autoimmune diseases.

Biocon’s products support key public health needs. It plays a strong role in drug innovation while maintaining accessibility for patients.

Key Business Areas

Biocon has four core areas: generics, biosimilars, novel biologics, and research services. The generics division makes affordable versions of common drugs. Biosimilars are developed as cost-friendly options to expensive biologics.

Syngene, its research arm, supports pharma companies with pre-clinical and clinical research. Biocon also works on original biologics for chronic conditions. Its full-scale model spans discovery to final manufacturing—making it one of India’s most integrated pharma companies.

Biocon Ltd. – Key Highlights

Mission & Vision

  • Vision: To improve healthcare worldwide through innovative, affordable medicines.

  • Mission: To become a world-class biotech company by excelling in research, quality manufacturing, clinical research, customer focus, global partnerships, and employee growth.

Milestones and Achievements

In 2024, Biocon Biologics crossed $1 billion in annual revenue. Growth came from more market share in the U.S. and expansion into new countries. In 2025, it launched Liraglutide in the UK to treat diabetes and obesity. These steps reflect Biocon’s aim to make life-saving drugs more accessible across the world.

Recent Developments or News

In April 2025, the European Commission approved Biocon Biologics' biosimilars Vevzuo and Evfraxy. These drugs treat bone conditions linked to cancer and giant cell tumour (GCT). The decision followed a positive review from the EU drug authority. This approval strengthens Biocon’s position in regulated markets.

Financial Overview of Biocon Ltd.

Revenue and Profit Trends

In FY25, Biocon posted revenue of ₹16,470 crore—up 5.4% from ₹15,621 crore in FY24. Net profit rose 10.1% to ₹1,429 crore. Higher sales, especially in international markets and biosimilars, drove growth.

Key Financial Ratios

Metric

Value

Return on Equity (%)

4.68

Return on Capital Employed (%)

6.04

Return on Assets (%)

1.72

Interest Coverage Ratio (x)

4.87

Asset Turnover Ratio (x)

0.27

Price to Earnings (x)

40.49

Price to Book (x)

1.89

EV/EBITDA (x)

13.87

EBITDA Margin (%)

28.66

Recent Quarterly/Annual Results

In Q4 FY25, revenue was ₹4,454 crore, up 12% YoY and 15% from the previous quarter. Core EBITDA was ₹1,363 crore with a margin of 31%. Net profit rose to ₹344 crore—up 153%. For the full year, revenue grew 5%, EBITDA rose to ₹4,374 crore, and adjusted net profit increased 30% YoY. R&D spending was ₹859 crore, showing Biocon’s long-term focus on innovation.

Biocon Ltd. Share Price Performance

Historical Share Price Trends

Biocon’s share price moved up in recent months. It was ₹354.45 on July 2, 2025, and averaged ₹372.40 recently. While it fell 0.55% in one week, it rose 9.14% over one month and 21.58% over three months. In three years, it returned 5.89%, behind the Nifty 50’s 55.47%.

52-Week High/Low

In the past year, Biocon’s lowest share price was ₹291.00 in October 2024. The highest was ₹404.70 in May 2025. These changes were linked to product approvals and investor confidence in its global business.

Price Volatility and Market Cap

As of 10th July 2025, Biocon's market cap stood at ₹49,788.53 crore. Beta values (volatility indicators) were:

  • 1 Month: 0.87

  • 3 Months: 1.37

  • 6 Months: 0.95

  • 1 Year: 0.98

  • 3 Years: 1.08

These show that Biocon’s stock has moderate volatility, especially over short terms.

Pros & Cons of Biocon Ltd.

Pros:

  • Strong product mix across biosimilars, generics, and research

  • Early entry in biologics gives it a market edge

Cons:

  • Return ratios are lower than industry leaders

  • High R&D costs and strict regulations affect margins

Biocon Ltd. Stock Fundamentals

P/E Ratio, EPS, ROE, etc.

Metric

Value

P/E Ratio (x)

49.13

EPS (TTM)

₹7.58

ROE

4.68%

ROCE

6.04%

P/B Ratio

2.37

Debt-to-Equity

0.82

Book Value

₹157.53

Face Value

₹5

Dividend Yield

0.13%

Dividend History

Biocon has paid dividends over 20 times since 2004. Its most recent was ₹0.50 per share (final), declared on May 8, 2025, with an ex-dividend date of July 4, 2025. Past dividends include regular and special payouts, such as ₹7.50 in 2013.

Shareholding Pattern

As of March 2025, the shareholding pattern in the company is as follows:

Shareholder Type

Percentage

Promoters

60.63%

Foreign Investors

17.88%

Mutual Funds

6.72%

Other Institutions

3.91%

Public & Others

10.86%

Competitors of Biocon Ltd.

Peer Comparison

Company

Price

MCap (Cr)

PE

P/B

ROE (%)

1-Yr Return

Net Profit (Cr)

Sales (Cr)

D/E

Biocon

372.40

49,788.53

49.13

2.36

4.68

2.59%

1,429

15,261

0.82

Concord Biotech

1,808.5

18,919.84

50.73

11.89

20.57

6.59%

372

1,200

0.00

Sun Pharma Adv

156.02

5,063.19

0.00

–36.21%

–342

71

–1.19

Windlas Biotech

908.80

1,904.78

31.40

4.04

11.99

22.75%

60

759

0.05

Softrak Venture

1.76

79.34

176.00

0.17

0.78

19.73%

0

2

0.00

Market Positioning

Biocon is among the largest Indian biotech companies by market value. With almost ₹50,000 crore in market cap, it has built strong expertise in biosimilars. It also exports to regulated markets like the U.S. and EU. Its leadership in insulin and oncology biosimilars supports its global reach.

Future Outlook for Biocon Ltd.

Growth Opportunities

Biocon is expanding across biosimilars, generics, and novel biologics. Its experience in fermentation and green chemistry gives it an edge. With the Viatris deal, it added scale and access in global markets. Biocon is also exploring growth in the GLP-1 diabetes and obesity drug category.

Risks and Challenges

Approval delays and pricing pressure affect revenue in global markets. The biosimilar space is seeing more players, which affects margins. R&D carries high risk—any failed trials can hit product pipelines. Currency swings and policy shifts in export markets add more risk.

How to Track Biocon Ltd.'s Share Price?

You can track Biocon’s share price live on NSE and BSE. Most financial platforms, apps, and brokerage websites show real-time charts and trade data. Visit www.biocon.com for earnings updates, regulatory filings, and investor presentations.

Share this article: 

Frequently Ask Questions

No Data Found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹6400+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|